SCHEMBL5111031

SCHEMBL5111031

COc1ccc2c(=O)c(C(C)=O)c(C)oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.58
CYP2C9 P11712 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C19 P33261 2/20 0.58
TSHR P16473 1/20 0.56
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
MAOA P21397 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
POLB P06746 2/20 0.55
KDM4E B2RXH2 8/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 4/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5277101 0.81 ALDH1A1 (0.68) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL4965650 0.81 KDM4E (0.64) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL9160809 0.80 ALDH1A1 (0.65) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL12715888 0.79 POLB (0.57) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL3661536 0.78 NPC1 (0.83) ALDH1A1CYP2C9CYP1A2CYP2C19NPC1
SCHEMBL29266618 0.78 ALDH1A1 (0.62) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL5241996 0.77 GAA (0.61) ALDH1A1CYP2C9CYP1A2CYP2C19TSHR
SCHEMBL28497661 0.77 NQO1 (0.65) ALDH1A1NPC1RAB9APOLBKDM4E
SCHEMBL11748869 0.76 CA1 (0.61) ALDH1A1TSHRNPC1RAB9AMAOA
SCHEMBL16654907 0.76 PTGS2 (0.69) ALDH1A1TSHRSMN1; SMN2POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329654-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-12 US disclosed
US-7329654-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-12 US disclosed
US-7329654-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-12 US disclosed
US-7105679-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators KANOJIA RAMESH M 2006-09-12 US disclosed
EP-1467998-B1 TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS ORTHO MCNEIL PHARM INC (US) 2006-03-29 EP disclosed
EP-1569939-A1 NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Ortho-Mcneil Pharmaceutical, Inc. (US) 2005-09-07 EP disclosed
US-20040259915-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators KANOJIA RAMESH M (US) 2004-12-23 US disclosed
EP-1467998-A1 TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-10-20 EP disclosed
WO-2004050660-A1 NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2004-06-17 WO disclosed
US-20030216463-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-20 US disclosed
WO-2003053977-A1 TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259915-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators GPER1, ESR2, FSHR ALDH1A1 2801/4885CYP2C9 1982/4885CYP1A2 731/4885
US-20030216463-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators GPER1, ESR2, FSHR ALDH1A1 2801/4885CYP2C9 1982/4885CYP1A2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.